Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis: A case report

Sara Maria Dalbjerg*, Anna Tsakiri, Jette Lautrup Fredriksen

*Corresponding author af dette arbejde
1 Citationer (Scopus)

Abstract

Background Multiple sclerosis is an inflammatory disease of the central nervous system for which there is currently no cure. Interferon-beta-1-alpha is worldwide one of the most widely used treatments in multiple sclerosis. To our knowledge there is one previous reported case of rhabdomyolysis associated with Interferon-beta treatment. Case presentation We describe a 30 year old man with relapsing remitting multiple sclerosis who developed rhabdomyolysis and increased creatine kinase following Interferon-beta-1-alpha therapy. After the medication was discontinued, the patient rapidly improved. Conclusion Clinicians should be aware of the possibility of rhabdomyolysis occurring during Interferon-beta-1-alpha therapy. In cases where patients complain of severe myalgia, and in particular if weakness is reported, creatine kinase activity should be measured to prevent irreversible rhabdomyolysis during Interferon-beta-1-alpha therapy in patients with multiple sclerosis.

OriginalsprogEngelsk
TidsskriftMultiple Sclerosis and Related Disorders
Vol/bind8
Sider (fra-til)93-95
Antal sider3
ISSN2211-0348
DOI
StatusUdgivet - jul. 2016

Fingeraftryk

Dyk ned i forskningsemnerne om 'Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis: A case report'. Sammen danner de et unikt fingeraftryk.

Citationsformater